Client: AdvanCell
Context: AdvanCell is an Australian radiopharmaceutical company that developing a revolutionary cancer treatment called Targeted Alpha Therapy (TAT), providing new hope for patients with cancers including prostate, skin, pancreatic, breast, bladder, colorectal, kidney, lung, and ovary.
The major limitation to the widespread adoption of TAT is the scalable supply of the isotopes required to make these therapies. AdvanCell’s targeted alpha therapies are powered by a platform technology – a world-first alpha isotope generator which addresses the greatest unmet need in targeted alpha therapy – the reliable and scalable supply of isotope.
